Fjarde Ap Fonden Alkermes Plc. Transaction History

Fjarde Ap Fonden

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$17.29 - $21.74 $573,785 - $721,463	-33,186 Closed	0 $0
Q3 2019 Oct 31, 2019	BUY	$19.51 - $24.28 $232,169 - $288,932	11,900 Added 55.91%	33,186 $647,000
Q2 2019 Jul 17, 2019	SELL	$21.47 - $37.33 $404,430 - $703,185	-18,837 Reduced 46.95%	21,286 $480,000
Q1 2019 Apr 29, 2019	SELL	$28.4 - $36.49 $58,049 - $74,585	-2,044 Reduced 4.85%	40,123 $1.46 Million
Q4 2018 Jan 31, 2019	SELL	$27.94 - $44.61 $206,756 - $330,114	-7,400 Reduced 14.93%	42,167 $1.24 Million
Q3 2018 Nov 09, 2018	SELL	$38.6 - $46.12 $77,508 - $92,608	-2,008 Reduced 3.89%	49,567 $2.1 Million
Q2 2018 Jul 12, 2018	BUY	$40.56 - $51.36 $94,139 - $119,206	2,321 Added 4.71%	51,575 $2.12 Million
Q1 2018 May 07, 2018	BUY	$53.61 - $67.26 $48,249 - $60,534	900 Added 1.86%	49,254 $2.86 Million
Q4 2017 Feb 12, 2018	BUY	$47.69 - $55.39 $244,840 - $284,372	5,134 Added 11.88%	48,354 $2.65 Million
Q3 2017 Nov 07, 2017	SELL	$49.16 - $54.45 $15,141 - $16,770	-308 Reduced 0.71%	43,220 $2.2 Million
Q2 2017 Aug 08, 2017	BUY	N/A	43,528	43,528 $2.52 Million

395

176M

558K

427K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.1B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.